Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia.
Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia.
复制标题
乳腺肿瘤中双调蛋白和调蛋白免疫染色的临床病理学分析。
DOI：
10.1023/a:1005845512804
复制
发表时间：
1997
影响因子：
3.8
通讯作者：
Reddy,KB
中科院分区：
文献类型：
--
作者：
Visscher,DW;Sarkar,FH;Kasunic,TC;Reddy,KB
在34例乳腺癌中，我们没有观察到肿瘤上皮细胞双调节素(AR)或糖蛋白(HRG)免疫染色与ER、EGFR/ERBB-2过表达、结节状态或疾病复发之间的关系。然而，两者的间质细胞染色与预后相关：29%的间质细胞AR⊖患者复发，而AR⊕患者为85%(P=0.001)，41%的间质细胞AR⊖患者复发，82%的AR⊕患者复发(P=0.01)。我们的结论是，HRG和AR在乳腺癌的生长和发展中都有重要的生物学作用，它们通过调节宿主-肿瘤的相互作用而有利于肿瘤的侵袭性行为。
We observed no association between neoplastic epithelial immunostainingfor either amphiregulin (AR) or heregulin (HRG) and presence of ER,EGFR/ERBB-2 overexpression, nodal status, or disease recurrence in 34 breastcarcinomas. However, stromal cell staining for both correlated with outcome;29% of stromal cell AR⊖ cases recurred vs. 85% forAR⊕ cases (p=0.001), and 41% of stromal cell HRG⊖cases recurred vs. 82% of HRG⊕ cases (p=0.01). Weconclude that both HRG and AR have significant biologic roles in breastcarcinoma growth or progression via mediation of host-tumor interactionswhich favor aggressive tumor behavior.